Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Neoadjuvant for ALK+ Resectable NSCLC
NCT05380024Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major Pathological Response at 12 weeks. Status: unknown.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05380024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380024.